Nuvectis Pharma (NVCT) Total Current Liabilities (2021 - 2026)

Nuvectis Pharma has reported Total Current Liabilities for 6 years, with the latest figure at $11.2 million in Q1 2026.

• Quarterly Total Current Liabilities rose 21.58% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 21.58% YoY) and the FY2025 annual result came in at $13.3 million, up 49.49% from the prior year.
• Total Current Liabilities fell to $11.2 million in Q1 2026 per NVCT's latest filing, from $13.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.3 million in Q4 2025 and troughed at $2.7 million in Q2 2022.
• A 5-year average of $7.0 million and a median of $6.2 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 155.73% in 2022, then advanced 12.9% in 2023.
• Over 5 years, Total Current Liabilities stood at $6.2 million in 2022, then advanced by 12.9% to $7.0 million in 2023, then advanced by 27.35% to $8.9 million in 2024, then jumped by 49.49% to $13.3 million in 2025, then decreased by 15.93% to $11.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $11.2 million, $13.3 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.